Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sildenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 19/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 3/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 3/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | PDE2A | O00408 | 1/20 | 1.00 |
| ▸ | ABCC5 | O15440 | 1/20 | 1.00 |
| ▸ | PDE6D | O43924 | 1/20 | 1.00 |
| ▸ | PDE8A | O60658 | 1/20 | 1.00 |
| ▸ | PDE9A | O76083 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | PDE6A | P16499 | 1/20 | 1.00 |
| ▸ | PDE6G | P18545 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PDE6B | P35913 | 1/20 | 1.00 |
| ▸ | PDE6C | P51160 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sildenafil SCHEMBL1895 | 1.00 | PDE5A (1.00) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL5683880 | 1.00 | PDE5A (1.00) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL584340 | 0.99 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL1801562 | 0.99 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL19410952 | 0.99 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL5691322 | 0.99 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL7915871 | 0.99 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL6689399 | 0.99 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL20544481 | 0.98 | PDE5A (0.97) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL3399278 | 0.98 | PDE5A (0.95) | PDE5APDE3BPDE3AABCC4PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387343-A1 | Nanoparticle Compositions and Methods for Synthesis Thereof | ICEUTICA PTY LTD (AU) | 2025-12-25 | — | — | US | claimed |
| EP-3731870-B1 | LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS | LIQMEDS LTD (GB) | 2025-11-12 | — | — | EP | claimed |
| CN-119970684-A | Sildenafil oral solution film and preparation method thereof | 四川科伦药物研究院有限公司 | 2025-05-13 | — | — | CN | claimed |
| EP-4719596-A1 | FUSION PROTEIN | Levicept Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720104-A1 | LOW AFFINITY P75 NEUROTROPHIC RECEPTOR EXTRACELLULAR DOMAIN FUSED TO A FC MOIETY AS NGF ANTAGONIST THERAPY OF PAIN | Levicept Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4712967-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4712957-A2 | ISOANDROGRAPHOLIDE ANALOGS AND METHOD FOR TREATMENT USING THE SAME | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250387343-A1 | Nanoparticle Compositions and Methods for Synthesis Thereof | ICEUTICA PTY LTD (AU) | 2025-12-25 | — | — | US | disclosed |
| EP-4662227-A1 | FUSION PROTEIN | Levicept Limited (GB) | 2025-12-17 | — | — | EP | disclosed |
| EP-3731870-B1 | LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS | LIQMEDS LTD (GB) | 2025-11-12 | — | — | EP | disclosed |
| EP-4630405-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4069691-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2022207673-A1 | SOS1 INHIBITORS AND RAS INHIBITORS FOR USE IN THE TREATMENT OF PAIN | SEVENLESS THERAPEUTICS LIMITED (GB) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022192487-A2 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-108883112-B | Compounds, compositions and methods for cancer patient stratification and cancer treatment | 拜耳医药股份公司 | 2022-07-26 | — | — | CN | disclosed |
| US-20220211626-A1 | REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-07-07 | — | — | US | disclosed |
| CN-114699528-A | Compositions and methods for PDE3A or SLFN12 expressing cancers | 布罗德研究所股份有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-114601837-A | Compounds, compositions and methods for cancer patient stratification and cancer treatment | 拜耳医药股份公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-108366947-B | Compositions and methods for PDE3A or SLFN12 expressing cancers | 布罗德研究所股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220023198-A1 | ORAL SOLUBLE FILM CONTAINING SILDENAFIL CITRATE | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387343-A1 | Nanoparticle Compositions and Methods for Synthesis Thereof | SAMM50, SI, TNNC1 | PDE5A 1799/4885PDE3B 1974/4885PDE3A 1226/4885 |
| US-20220023198-A1 | ORAL SOLUBLE FILM CONTAINING SILDENAFIL CITRATE | PDE12, SORD, PDE5A | PDE5A 3/4885PDE3B 6/4885PDE3A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.